MX2019008489A - Tratamiento que comprende la administracion oral o gastrica de edaravona. - Google Patents
Tratamiento que comprende la administracion oral o gastrica de edaravona.Info
- Publication number
- MX2019008489A MX2019008489A MX2019008489A MX2019008489A MX2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A MX 2019008489 A MX2019008489 A MX 2019008489A
- Authority
- MX
- Mexico
- Prior art keywords
- edaravone
- treatment
- oral
- gastric administration
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a una composición farmacéutica líquida para su uso en tratamiento médico, siendo dicha composición farmacéutica líquida una solución acuosa monofásica de 3-metil-1-fenil-2-pirazolin-5-ona no complejada (edavarona) y que comprende al menos un 75 % en peso de agua y 0,2-9 mg/ml de edaravona, en la que el tratamiento comprende la administración oral o gástrica de 10-250 ml de la composición farmacéutica líquida para proporcionar 30-300 mg de edaravona.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17151741 | 2017-01-17 | ||
PCT/EP2017/067005 WO2018133957A1 (en) | 2017-01-17 | 2017-07-06 | Medical treatment comprising enteral administration of edaravone |
EP17180087 | 2017-07-06 | ||
PCT/EP2018/051097 WO2018134243A1 (en) | 2017-01-17 | 2018-01-17 | Treatment comprising oral or gastric administration of edaravone |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008489A true MX2019008489A (es) | 2019-11-11 |
Family
ID=62908293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008489A MX2019008489A (es) | 2017-01-17 | 2018-01-17 | Tratamiento que comprende la administracion oral o gastrica de edaravona. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190328712A1 (es) |
EP (2) | EP3785703A1 (es) |
JP (2) | JP7107624B2 (es) |
KR (1) | KR102550376B1 (es) |
AU (1) | AU2018209155B2 (es) |
BR (1) | BR112019014705A2 (es) |
CA (1) | CA3050037A1 (es) |
DK (1) | DK3551181T3 (es) |
ES (1) | ES2850873T3 (es) |
IL (1) | IL268127A (es) |
MX (1) | MX2019008489A (es) |
PL (1) | PL3551181T3 (es) |
RU (1) | RU2761967C2 (es) |
WO (1) | WO2018134243A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3551181T3 (da) * | 2017-01-17 | 2020-11-30 | Treeway Tw001 B V | Behandling omfattende oral eller gastrisk indgivelse af edaravone |
ES2868955T3 (es) | 2017-01-17 | 2021-10-22 | Treeway Tw001 B V | Tratamiento médico que comprende la administración enteral de edaravona |
CN110996944A (zh) * | 2017-07-06 | 2020-04-10 | 萃微Tw001公司 | 依达拉奉在口服治疗氧化应激介导的神经退行性疾病中的用途 |
US11826352B2 (en) | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
BR112021008197A2 (pt) | 2018-11-02 | 2021-08-03 | Mitsubishi Tanabe Pharma Corporation | suspensão de edaravone para administração oral |
KR20230098267A (ko) * | 2020-11-12 | 2023-07-03 | 미쓰비시 타나베 파마 코퍼레이션 | 에다라본 경구 투여용 의약 조성물 및 그의 투여 방법 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3758164B2 (ja) | 2000-10-24 | 2006-03-22 | 三菱ウェルファーマ株式会社 | 筋萎縮性側索硬化症(als)治療剤 |
JP2004002400A (ja) | 2002-04-23 | 2004-01-08 | Mitsubishi Pharma Corp | 軽微低体温療法を行うために用いる脳保護及び/又は脳機能正常化のための医薬 |
JP2004091441A (ja) | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | ピラゾロン誘導体を含有する経口投与製剤 |
PT1714960T (pt) | 2004-02-09 | 2018-05-02 | Mitsubishi Tanabe Pharma Corp | Um agente terapêutico inovador para a esclerose lateral amiotrófica (ela) ou doenças provocadas pela ela |
JP2008280253A (ja) | 2007-05-08 | 2008-11-20 | Ohara Yakuhin Kogyo Kk | エダラボン注射液 |
JP2009143902A (ja) | 2007-11-21 | 2009-07-02 | Kowa Co | エダラボンを含有する安定な水溶性製剤 |
CN101801195A (zh) * | 2007-11-21 | 2010-08-11 | 帝国制药美国公司 | 吡唑啉酮衍生物乳液制剂 |
JP2009143922A (ja) | 2007-11-22 | 2009-07-02 | Fujiyakuhin Co Ltd | 注射剤 |
JP2009155315A (ja) | 2007-12-26 | 2009-07-16 | Fujiyakuhin Co Ltd | 注射剤 |
JP2009280561A (ja) | 2008-05-26 | 2009-12-03 | Fujiyakuhin Co Ltd | 注射剤 |
JP2010047482A (ja) * | 2008-08-19 | 2010-03-04 | Ohara Yakuhin Kogyo Kk | エダラボン注射液 |
JP2010077104A (ja) | 2008-08-29 | 2010-04-08 | Nihon Pharmaceutical Co Ltd | 3−メチル−1−フェニル−2−ピラゾリン−5−オン注射用水溶液 |
WO2010059727A1 (en) * | 2008-11-20 | 2010-05-27 | Teikoku Pharma Usa, Inc. | Pyrazalone derivative formulations |
CN101953832B (zh) | 2010-08-10 | 2012-02-15 | 南京师范大学 | β-环糊精包合依达拉奉的口服药物组合物及其制备方法 |
CN102349893A (zh) * | 2011-08-19 | 2012-02-15 | 福建天泉药业股份有限公司 | 依达拉奉药物组合物 |
HUE044369T2 (hu) | 2011-09-05 | 2019-10-28 | Mitsubishi Tanabe Pharma Corp | Gyógyászati szer izomsorvadásos laterálszklerózis kezelésére vagy izomsorvadásos laterálszklerózis súlyosbodásának megelõzésére |
CN105816423B (zh) | 2016-03-16 | 2018-07-20 | 福建天泰医药科技有限公司 | 依达拉奉剂型 |
DK3551181T3 (da) * | 2017-01-17 | 2020-11-30 | Treeway Tw001 B V | Behandling omfattende oral eller gastrisk indgivelse af edaravone |
-
2018
- 2018-01-17 DK DK18701303.2T patent/DK3551181T3/da active
- 2018-01-17 RU RU2019125848A patent/RU2761967C2/ru active
- 2018-01-17 ES ES18701303T patent/ES2850873T3/es active Active
- 2018-01-17 CA CA3050037A patent/CA3050037A1/en active Pending
- 2018-01-17 KR KR1020197020834A patent/KR102550376B1/ko active IP Right Grant
- 2018-01-17 JP JP2019559390A patent/JP7107624B2/ja active Active
- 2018-01-17 WO PCT/EP2018/051097 patent/WO2018134243A1/en active Search and Examination
- 2018-01-17 MX MX2019008489A patent/MX2019008489A/es unknown
- 2018-01-17 EP EP20201851.1A patent/EP3785703A1/en active Pending
- 2018-01-17 EP EP18701303.2A patent/EP3551181B1/en active Active
- 2018-01-17 PL PL18701303T patent/PL3551181T3/pl unknown
- 2018-01-17 AU AU2018209155A patent/AU2018209155B2/en active Active
- 2018-01-17 BR BR112019014705-5A patent/BR112019014705A2/pt active Search and Examination
-
2019
- 2019-07-12 US US16/510,518 patent/US20190328712A1/en active Pending
- 2019-07-17 IL IL268127A patent/IL268127A/en unknown
-
2022
- 2022-07-11 JP JP2022111202A patent/JP7415236B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP7415236B2 (ja) | 2024-01-17 |
EP3551181A1 (en) | 2019-10-16 |
DK3551181T3 (da) | 2020-11-30 |
ES2850873T3 (es) | 2021-09-01 |
JP2022137179A (ja) | 2022-09-21 |
AU2018209155B2 (en) | 2023-11-30 |
EP3551181B1 (en) | 2020-11-18 |
RU2019125848A3 (es) | 2021-04-12 |
US20190328712A1 (en) | 2019-10-31 |
EP3785703A1 (en) | 2021-03-03 |
AU2018209155A1 (en) | 2019-08-01 |
WO2018134243A1 (en) | 2018-07-26 |
CA3050037A1 (en) | 2018-07-26 |
KR102550376B1 (ko) | 2023-07-04 |
RU2761967C2 (ru) | 2021-12-14 |
RU2019125848A (ru) | 2021-02-19 |
JP2020506959A (ja) | 2020-03-05 |
JP7107624B2 (ja) | 2022-07-27 |
BR112019014705A2 (pt) | 2020-02-18 |
PL3551181T3 (pl) | 2021-05-31 |
IL268127A (en) | 2019-09-26 |
KR20190111929A (ko) | 2019-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008489A (es) | Tratamiento que comprende la administracion oral o gastrica de edaravona. | |
MX2021004431A (es) | Procesos novedosos. | |
CR20200553A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
PH12019502095A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
MX2019012884A (es) | Terapia de combinacion. | |
PH12017500479B1 (en) | Liquid inhalation formulation comprising rpl554 | |
PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
WO2015038533A3 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
PH12020500091A1 (en) | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer | |
MX2019004280A (es) | Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina. | |
CO2016003340A2 (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
PH12020550775A1 (en) | Pentosan polysulfate and medicine containing pentosan polysulfate | |
MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
MX2019008482A (es) | Tratamiento medico que comprende administracion enteral de edaravona. | |
MX368735B (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. | |
AR111803A1 (es) | Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino | |
MY188302A (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
MX2022002185A (es) | Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso. |